Has Andrew Eiseman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $871 in general payments to Andrew Eiseman, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Eiseman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Eiseman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Eiseman, MD

Ophthalmic Plastic and Reconstructive Surgery · Charleston, SCNPI 1013098987

Payments from drug & device makers

$871in general payments, 2019–2025

Across 8 payments — averaging $108.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alimera Sciences, Inc.$279
Alcon$175
Amgen$168
Omeros Corporation$120
Bausch & Lomb, A Division Of Bausch Health US, LLC$111
AbbVie$18

What the payments were for

Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alimera Sciences, Inc.	2	$279
Alcon	2	$175
Amgen	1	$168
Omeros Corporation	1	$120
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$111
AbbVie	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$143,076

Medicare patients

454

Services billed

1,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XiidraLifitegrast	28	$19,006
Cyclosporine	31	$13,777
Doxycycline Hyclate	30	$541
Tobramycin-DexamethasoneTobramycin/Dexamethasone	18	$491
Latanoprost	34	$450
ErythromycinErythromycin Base	27	$283
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	16	$137

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Charleston

Eric BermanCharleston$654
Rakesh PatelColumbia$108K
Allison PariyadathGreenville$2K
Garrison WierGreenville$1K
Kip DolphinGreenville$52

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →